Table 2.
Status of vaccines in development against SARS-CoV-2.
| Developer | Molecular target | Phase of clinical trial | References |
|---|---|---|---|
| Biontech | mRNA Vaccine | Phase I | Biontech (2020) |
| Hoth Therapeutics | Self-assembling Vaccine | Pre-Clinical | Hoth (2020) |
| Moderna | mRNA Vaccine | Phase I | clinicaltrials.gov (2020j) |
| Johnson&Johnson | COVID-19 Vaccine | Pre-Clinical | Chen et al. (2020) |
| CanSinoBIO | COVID-19 Vaccine | Phase I | CanSinoBIO (2020) |
| Inovio | COVID-19 Vaccine | Phase I | (Amanat and Krammer, 2020; WHO, 2020a) |
| Janssen Pharmaceutical | Non-replicating viral vector | Pre-clinical | WHO (2020a) |
| Clover Biopharmaceuticals Inc./GSK | Protein subunit; S trimer | Pre-clinical | GSK (2020) |
| University of Oxford | Non-replicating viral vector; ChAdOx1 | Phase I | Lane (2020) |
| Sinovac | Formaldehyde in activated + alum | Phase I | sinovac (2020) |
| Codagenix/Serum Institute of India | Deoptimized live attanuated vaccines | Pre-clinical | WHO (2020a) |
| Novavax | Full length S trimers/nanoparticle + Matrix M | Pre-clinical | Novavax (2020) |
| Vaxart | Non-replicating viral vector; | Pre-clinical | Vaxart (2020) |